Literature DB >> 17255825

Infliximab use and hepatosplenic T cell lymphoma: questions to be asked and lessons learned.

Joel R Rosh, Maria Oliva-Hemker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17255825     DOI： 10.1097/MPG.0b013e318031d61a

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN： 0277-2116            Impact factor:   2.839


× No keyword cloud information.
  8 in total

1.  Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?

Authors:  Stephen B Hanauer
Journal:  Gut       Date:  2007-09       Impact factor: 23.059

Review 2.  Update on the management of Crohn's disease.

Authors:  Anna M Buchner; Wojciech Blonski; Gary R Lichtenstein
Journal:  Curr Gastroenterol Rep       Date:  2011-10

3.  T cell lymphoproliferative disorders associated with anti-tumor necrosis factor alpha antibody therapy for ulcerative colitis: literature summary.

Authors:  Lindsay A Schmidt; Megan S Lim
Journal:  J Hematop       Date:  2009-03-18       Impact factor: 0.196

4.  Diagnostic ionizing radiation exposure in a population-based sample of children with inflammatory bowel diseases.

Authors:  Lena Palmer; Hans Herfarth; Carol Q Porter; Lynn A Fordham; Robert S Sandler; Michael D Kappelman
Journal:  Am J Gastroenterol       Date:  2009-08-18       Impact factor: 10.864

5.  Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience.

Authors:  Martin H Voss; Matthew A Lunning; Jocelyn C Maragulia; Esperanza B Papadopoulos; Jenna Goldberg; Andrew D Zelenetz; Steven M Horwitz
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-10-27

Review 6.  Clinical pharmacokinetics and use of infliximab.

Authors:  Ulrich Klotz; Alexander Teml; Matthias Schwab
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

7.  Biologic therapy for inflammatory bowel disease comes of age.

Authors:  Stephen B Hanauer
Journal:  Curr Gastroenterol Rep       Date:  2007-12

8.  Epstein-Barr virus seroprevalence and viral load at disease onset in children with inflammatory bowel disease.

Authors:  Gaël Kornitzer; Michelle Rosenstein; Marie-Catherine Turcotte; David Godin; Véronique Groleau; Christian Renaud; Fabien Touzot; Prevost Jantchou; Philippe Ovetchkine; Colette Deslandres
Journal:  JGH Open       Date:  2022-07-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.